FLT3 and acute myeloid leukemia: In addition, a genome-wide CRISPR screen revealed that reduction of GSK3 enhanced drug resistance to ACC20, a selective inhibitor of FLT3, in AML patients, suggesting that inhibition of GSK3 may reduce the efficiency of clinical treatment with FLT3 inhibitors [27].